Roivant Sciences in talks to sell bowel disease drug to Roche in over USD 7 bilion deal: Report
RVT-3101 showed improvement in inflammation and ulcers in colon, when compared to placebo, in a mid-stage study in June.
Basel: Biotech company Roivant Sciences is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease to Roche in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday.
The sale of the drug could be announced in the coming days, the report said, citing people familiar with the matter. The talks could still fall apart and another suitor could swoop in, it added.
Roivant's experimental drug, RVT-3101, is under clinical trials for the treatment of moderate-to-severe ulcerative colitis, a long-term condition where the colon and rectum become inflamed, as well as a type of inflammatory bowel disease known as Crohn's disease.
RVT-3101 showed improvement in inflammation and ulcers in colon, when compared to placebo, in a mid-stage study in June.
Roivant declined to comment, whereas Roche did not immediately respond to a Reuters request for comment.
Read also: Roche gets European Commission nod for fixed duration Columvi for diffuse large B-cell lymphoma
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.